Background. Understanding anti-non-gal antibody response is of significance for success in xenotransplantation. Long-term anti-non-gal response in humans was studied in patients transplanted with porcine patellar tendon (PT) lacking ␣-gal epitopes, for replacing ruptured anterior cruciate ligament (ACL). Methods. Porcine PTs were treated with recombinant ␣-galactosidase to eliminate ␣-gal epitopes and with glutaraldehyde for moderate cross-linking of collagen fibers. The processed pig PTs were implanted to replace ruptured ACL in patients. Results. In five of six evaluable subjects, the xenografts have continued to function for over two years and passed all functional stability assessments. Thus, processed porcine PT seems to be appropriate for replacing ruptured human ACL. Enzyme-linked immunosorbent assay and Western blot studies indicated that all subjects produced anti-non-gal antibodies against multiple pig xenoproteins, but not against human ligament proteins. Production of anti-non-gal antibodies peaked two to six months posttransplantation and disappeared after two years. Conclusions. These antibodies contribute to a low-level inflammatory process that aids in gradual xenograft replacement by infiltrating host fibroblasts that align with the pig collagen "scaffold" and secrete collagen matrix. The assays monitoring anti-non-gal antibodies will help to determine whether long-term survival of live organ xenografts requires complete suppression of this antibody response.
I
nteraction between the natural anti-Gal antibody and ␣-gal epitopes (Gal␣1-3Gal␤1-4GlcNAc-R) is a major obstacle in pig-to-human xenotransplantation (1) (2) (3) (4) . Cloning of knockout pigs lacking ␣-gal epitopes has eliminated the anti-Gal immune barrier to xenotransplantation (5, 6) . Xenotransplantation from these pigs into monkeys displayed prolonged activity of pig hearts for up to six months (7, 8) , pig kidneys for 8 -32 days (9, 10) , and pig kidneys containing vascularized thymic tissue for up to 83 days (9) . Immunohistology of the rejected knockout xenografts demonstrated antibody deposits (7) (8) (9) (10) . These antibodies which interact with xenoproteins have been previously demonstrated in humans (11) and monkeys transplanted with xenografts (12) (13) (14) (15) (16) and have been designated anti-non-gal antibodies (10 -16) . Their production implies that xenografts with no ␣-gal epitopes continue to be immunogenic and that currently used immunosuppression does not prevent production of anti-non-gal antibodies. These observations have raised the questions of whether humans transplanted with pigs xenografts continuously produce anti-non-gal antibodies and can xenografts be successful in humans despite production of these antibodies. We addressed these questions in patients transplanted with porcine patellar tendon (PT) to replace ruptured anterior cruciate ligament (ACL). The primary objective of this study was to evaluate the long term immune response in humans against the implanted pig tissue and identify changes occurring as a result of this immune response. We monitored the anti-xenograft immune response in these subjects for two years. In addition to the demonstration of successful reconstruction of ACL with porcine PT, this study provides information on the long-term immune response to pig xenografts in humans.
The ACL is the key stabilizer of knee joints. More than 300,000 damaged ACLs undergo surgical intervention in the United States each year. Current techniques include bonepatellar tendon-bone ligament autograft harvested from the noninjured knee for reconstructing the ACL and, less frequently, cadaveric tissue allografts. Both techniques have disadvantages and risks. Reconstruction utilizing autologous harvest procedure involves a second surgical site. The harvest procedure often results in increased pain, longer recovery periods, and increased morbidity. Complications may include patella fracture, patellar tendon rupture, and scar formation (17, 18) . Cadaveric tissue allografts offer a limited source of ACL replacement tissue due to scarcity of available tissue from young, healthy donors. The perceived risk of transmission of hepatitis and other diseases is another obstacle to the acceptance of cadaveric tissue.
Autologous PT grafts replacing ACL undergo sequential changes collectively referred to as "ligamentization" (19, 20) . Ligamentization is initiated by the necrosis of fibroblasts within the ligament, because of the ischemia in the ligament removed from the uninjured knee. The cell necrosis induces local inflammation that is followed by repopulation by infiltrating fibroblasts which orient themselves along the collagen fibers "scaffold" and secrete collagen and other matrix pro-teins. In parallel with the inflammatory process and fibroblast repopulation, new blood vessels appear within the ligament. This revascularization provides oxygen and nutrients to fibroblasts that repopulate the various regions of the ligament. The ongoing inflammatory process, concomitant fibroblast repopulation and collagen secretion ultimately result in gradual remodeling of collagen fibers into those characteristic to ACL (19, 20) . We hypothesized that porcine PT may be processed in a way that will attenuate the immune response against this xenograft to a level that enables appropriate ligamentization. This processing includes two steps: 1) enzymatic elimination of ␣-gal epitopes from the porcine ligament by recombinant ␣-galactosidase, in order to prevent anti-Gal mediated rejection of the xenograft; and 2) moderate crosslinking of collagen fibers by glutaraldehyde to attenuate the immune response and slow anti-non gal directed infiltration of inflammatory cells destroying the pig xenograft, thereby allowing for an appropriate pace of ligamentization.
This study demonstrates transplantation of processed porcine PT to replaced ruptured ACL in humans, in the absence of any immunosuppressive treatment. The study has enabled the long-term monitoring of anti-non-gal antibodies produced against pig xenoantigens in human recipients.
MATERIALS AND METHODS

Processing of Porcine Ligaments
The porcine PT ligaments with attached bone plugs (bone-patellar tendon-bone, length of ϳ10 cm and width of ϳ1 cm) kept frozen in saline, were thawed at room temperature. The saline was replaced with recombinant ␣-galactosidase (100 units/mL, in citrate buffer pH 6.0, ZymeQuest Inc. Beverly, MA) (21, 22) containing 30% polyethylene glycol (PEG) and 400 mg/L Cefazolin. The porcine ligaments were incubated within the enzyme solution for 12 hr at 26°C. Subsequently, the ligaments were extensively washed with phosphate-buffered saline (PBS) to remove the enzyme and immersed for 12h at 4°C in PBS solution containing 0.1% glutaraldehyde (Sigma Chemicals, St. Louis MO). Ligaments were then washed with PBS and immersed in PBS containing 0.1 M glycine for 24 hr at 4°C in order to block the remaining reactive groups of glutaraldehyde molecules. The entire procedure is carried out under sterile conditions. Ligaments were stored at Ϫ70°C in 30% propylene glycol and 0.1 M glycine in PBS within Amylar-bonded foil pouches.
Subsequently, the ligaments were irradiated by E-beam (17.8 kGy) for final sterilization.
Patient Population
The average age of the study group was 41 years (range of 21 to 51) and the group consisted of seven males and three females (Table 1) . Of the group, five had acute (Ͻ3 months) and five had chronic ACL ruptures. Two of the subjects had a previous autograft ACL reconstruction, and were deemed as revision cases, one subject had a previous ACL repair, and three subjects had previous ACL surgery on the contralateral knee. The study group was a highly active and athletic subject population. All subjects were evaluated for general and systemic health throughout the study period to assess the safety of the device. To date, and in the analysis presented herein, study data has been analyzed using 24 month follow-up results for all 10 subjects.
Surgical Procedure
Processed porcine PTs were implanted in patients with ruptured ACL through a procedure identical to ACL reconstruction with autografts. A complete diagnostic arthroscopy of the entire knee joint was performed. Any associated meniscal or articular cartilage damage was repaired or resected. The damaged ligament was removed with an arthroscopic shaver. A notchplasty was performed if there was notch impingement with the knee held in full extension. A ligament guide was used to identify the anatomic insertion sites on the femur and tibia. A guide pin was placed at each site and overdrilled with a 10-mm bit. The tibial tunnel was placed to position the PT ligament anatomically within the fibers of the original ACL and without roof impingement. The femoral tunnel was placed within the original ACL insertion and in the posterior one-quarter of the femoral condyle. The edges of the drill hole were smoothed and a ligament passer was placed. The bone ends of the processed porcine PT were trimmed and the PT was pulled into place and fixed with 9ϫ20 mm Kurosaka design titanium interference fit screws (Mitek, Raynham, MA). The knee was moved through a full range of motion to ensure that there was no impingement and was manually tested for stability. If impingement was noted, a further notchplasty was performed. The patients underwent periodic clinical examinations, radiographic and magnetic resonance imaging examinations, and blood and urine analysis for each subject for a two-year period following surgery. Measuring ␣-gal Epitope Expression in Ligaments Treated with Recombinant ␣-galactosidase Detection of ␣-gal epitopes within treated ligaments was performed by the enzyme linked immunosorbent assay (ELISA) inhibition (12, 23) . Pig ligaments were homogenized, brought to a concentration of 200 mg/mL, subjected to serial twofold dilutions and mixed with equal volume of monoclonal anti-Gal M86 antibody diluted 1:100 (23). The mixture was incubated in microfuge tubes overnight at 4°C with constant rotation. Subsequently, fragments and bound anti-Gal were removed by centrifugation. The activity of free monoclonal anti-Gal remaining in the supernatant was determined in ELISA wells coated with ␣-gal epitopes linked to bovine serum albumin (␣-gal BSA, Dextra, Reading UK) as solid phase antigen, using horseradish peroxidase (HRP)-conjugated goat anti-mouse IgM antibody (Accurate Chemical, Westbury NY) as secondary antibody. The ligament fragments expressing ␣-gal epitopes bind the antibody proportional to the number of ␣-gal epitopes expressed in the ligament. The results are expressed as the proportion of monoclonal anti-Gal antibody adsorbed by the fragmented ligament (% inhibition of binding in ELISA). If all ␣-gal epitopes are removed from the ligaments, no anti-Gal is adsorbed, i.e. % inhibitionϭ0.
Assay for Anti-non-gal Antibodies
Anti-non-gal antibodies were determined by ELISA as previously described (12) . The tested sera were depleted of anti-Gal antibodies, prior to the assay, by adsorption on an equal volume of glutaraldehyde fixed rabbit red cells. Homogenized pig ligament fragments were brought to a concentration of 2 mg/mL in carbonate buffer pH 9.5 and dried overnight in 50 l aliquots in ELISA wells. The dried ligament fragments adhere strongly to the ELISA wells and serve as an effective solid phase antigen. ELISA wells were blocked with 1% BSA in PBS and 50-l aliquots of sera were placed into ELISA wells in serial twofold dilutions in PBS/BSA. After two hours incubation, plates were washed. HRP coupled rabbit antihuman IgG, or anti-human IgM antibodies (Dako, Copenhagen, Denmark) were used as secondary antibodies.
Assay for Anti-Gal Antibodies
Anti-Gal IgG production was measured as previously described (12) . ELISA wells were coated with 10 g/ml ␣-gal-BSA as solid phase antigen and blocked with PBS/BSA solution. Anti-Gal activity was determined in sera placed into ELISA wells at serial twofold dilutions in PBS/BSA. Binding of anti-Gal IgG and IgM antibodies was determined as in assays measuring anti-non gal antibodies described above.
Western Blot Analysis
Proteins were extracted from 50 mg/ml of fragmented pig ligament, pig kidney and human cadaveric ligament. The extract was electrophoresed in 10% SDS-PAGE and then analyzed by standard Western blotting. The proteins were transferred to polyvinylidene fluoride membranes (S&S, Keene, NH) by semidry blotting system, and the membranes were blocked overnight with PBS containing 3% defatted milk and incubated with serum samples obtained pretransplantation, or six months posttransplantation. The sera were depleted of anti-Gal antibodies by preadsorption on glutaraldehyde fixed rabbit red blood cells and were diluted 1:10 in PBS containing 1% BSA. The blots were incubated for two hours with the diluted sera, washed, and antibody binding was detected by HRP conjugated anti-human IgG, followed by diaminobenzidine color reaction.
RESULTS
Removal of ␣-gal Epitopes from Porcine Ligament by ␣-Galactosidase
The porcine PT ligament is nominally 10 cm in length and 1.0 cm in width and is attached to patellar and tibial bone plugs (Fig. 1A) . Elimination of ␣-gal epitopes from these ligaments was achieved by 12h incubation with 100 units/ml recombinant ␣-galactosidase at 26 o C. The remaining Nacetyllactosamine (Gal␤1-4GlcNAc-R) on carbohydrate chains is not immunogenic since it is normally present on human cells. Elimination of ␣-gal epitopes from porcine PT was assessed by binding of monoclonal anti-Gal to ␣-gal epitopes on ligament fragments in the ELISA inhibition assay (12, 23, 24) . Untreated pig ligaments express an abundance of ␣-gal epitopes as indicated by the 50% of inhibition of monoclonal anti-Gal binding at a fragment concentration of 12.5 mg/ml (Fig. 1B) . This binding is similar to that previously reported for pig meniscus cartilage (12) , implying that pig PT ligament has ϳ10
11 ␣-gal epitopes/mg. Ligaments incubated for 12 hr with ␣-galactosidase had no ␣-gal epitopes, thus their fragments did not bind monoclonal anti-Gal even at their highest concentration of 200 mg/ml (i.e. 0% inhibition in Figure 1B) . Incubation with ␣-galactosidase for only two hr and four hr resulted in ␣-gal eliminations of 88% and 95%, respectively. This was indicated by 50% inhibition of anti-Gal binding with ligament fragments after two hr incubation at 100 mg/mL (i.e., eightfold higher concentration than untreated ligament fragments), and 50% inhibition after four hr incubation at 200 mg/mL (i.e. 16-fold decrease in ␣-gal epitope concentration). Since sensitivity of the ELISA inhibition assay is limited to detection of at least 10 9 ␣-gal epitopes/mg tissue (23), our data suggest that 12 hr incubation with ␣-galactosidase resulted in the elimination of Ͼ99% of the ␣-gal epitopes in the porcine ligament.
Clinical Outcome of the Porcine PT Transplantation
The xenograft and surgery were well tolerated by all patients. Subjects were aggressive in rehabilitation and rapidly returned to full sports activities early in the postoperative period. At the 24-month postoperative time point, five of six evaluable subjects (Table 1) presented with functional grafts that were satisfactory in a variety of standard orthopedic tests and lacked knee effusions, which if preset would reflect extensive inflammation. One of these six subjects presented with tibial bone plug loosening at 15 months postimplantation and had his xenograft removed. Four subjects were nonevaluable due to nondevice-related complications during the study, as follows: two unfortunate retraumas at 3.5 and 8.5 months postoperatively resulting from biking and skiing accidents, and two technical/surgical complications not related to the treated xenograft device (Table 1 ). Blood chemistry, urine chemistry, and serology results of all patients were within acceptable normal ranges at the 24-month time point.
Anti-non-gal Antibody Response to Pig Ligament Xenograft
Anti-non-gal antibody response to the xenograft was evaluated by ELISA with fragmented pig ligament as solidphase antigen. The presented results are for the five evaluable patients from whom the pig PT was not removed (Fig. 2) . All subjects displayed a baseline low-level pretransplantation IgG antibody binding to ELISA wells. Since the sera were depleted of anti-Gal, this background binding at low serum dilutions is likely to represent low level of IgG binding which can not be avoided in wells blocked with BSA. This is further supported by the lack of antibody binding observed with pretransplantation sera that were assayed for IgG binding to the pig ligament proteins in Western blots (Fig. 3A) . All recipients displayed increased anti-non-gal antibody activity posttransplantation. This response varied in different subjects, and usually peaked 2-6 months posttransplantation (summarized in Fig. 2F for serum dilution of 1:640). Anti-non-gal activity decreased by 12 months, and with the exception of patient P-10, returned to pretransplantation level after 24 months. This decrease at 12 and 24 months probably reflects a corresponding elimination of immunogenic pig xenoproteins due to ligamentization.
Anti-non-gal IgM analysis demonstrated much lower variations in the various time points. This is indicated in data from one representative subject (P-10) in Figure 2G and as summary of data from all five patients at serum dilution of 1:80 in Figure 2H . The lack of significant changes in anti-non-gal IgM response may result from rapid isotype switch of the corresponding activated B cells from IgM to IgG producing cells.
We do not have at this time the ability to compare the anti-non-gal response in these patients with that in allograft recipients, in order to exclude the possibility that these antibodies are the result of nonspecific B cell activation. Nevertheless, in studies we have performed in rhesus monkeys, we have observed no anti-non-gal antibody response in allograft recipients. In contrast, monkeys implanted with porcine PT produced anti-non-gal antibodies in titers similar to those found above in humans (in preparation). These findings strongly suggest that anti-non-gal antibody response is unique to recipients of xenografts.
In order to determine specificity of the elicited antinon-gal antibodies, sera were assayed for antibody binding to pig proteins separated on SDS-PAGE gel and blotted in Western blots (Fig. 3 ). Proteins were extracted from homogenates of pig ligament, pig kidney, and human ligament. The same protein preparations were used in blots A-D of Figure 3 for analysis of anti-non-gal antibody activity. Sera were depleted of anti-Gal and subjected to Western blot immunostaining. Pretransplantation sera displayed no significant antibody binding to the Western blots of pig ligament, pig kidney, or human ligament proteins (Fig. 3A) . It should be stressed that anti-Gal IgG activity in pretransplantation of patient P-10 was too low to yield binding to the ␣-gal epitopes on pig ligament and pig kidney glycoproteins. Thus, staining with the pretransplantation sera containing anti-Gal was negative, similar to that in Figure 3A . Nevertheless, anti-Gal was removed also from posttransplantation sera (Fig. 3B and C) , to ensure the exclusion of any elicited anti-Gal binding to glycoproteins with ␣-gal epitopes. Sera obtained 6 months posttransplantation displayed extensive antibody binding to many pig ligament proteins, as indicated by the multiple bands representing proteins of different size ( Fig. 3B and C) . In some of the areas within the blots, many of the immunogenic pig ligament proteins migrate close to each other because of similarities in size. Therefore, the boundaries between some of the bands representing individual proteins binding anti-non-gal antibodies may not be distinct. Some of the antibody binding proteins were present also in pig kidney. This is to be expected since many pig proteins that are immunogenic in humans, are likely to be shared by various pig tissues. No antibodies bound to human ligament proteins, implying that the xenograft does not elicit autoantibodies to human ligament antigens. A similar lack of autoantibody activity was observed in ELISA with human ligament fragments as solid phase antigen, using sera from all time points (not shown). 
Anti-Gal Immune Response to Pig Ligament Xenograft
Elicited anti-Gal IgG response in humans receiving xenografts is a very sensitive measure for presence of ␣-gal epitopes on the graft (11, 25) . All five porcine PT ligament recipients displayed a two-to eightfold increase in anti-Gal IgG activity by two weeks posttransplantation (Fig. 4A and   B ). This anti-Gal response was much weaker than the 30-to 100-fold increase in anti-Gal activity in recipients of xenograft cells expressing ␣-gal epitopes (11, 25) . In previous studies we have shown that implantation of ␣-galactosidase treated pig cartilage (in the absence of bone tissue) into rhesus monkeys induces no anti-Gal response (12) . Removal of ␣-gal epitopes in the porcine PT was performed by the same method, and the ligament was found to be devoid of ␣-gal epitopes (Fig. 1B) . Based on these considerations, it is possible that the observed anti-Gal production resulted from stimulation by ␣-gal epitopes expressed on bone marrow cells which are enclosed in bone cavities within the ligament bone plugs that which may not be accessible to ␣-galactosidase (Fig. 4D) . These bone marrow cells release into the circulation glycoproteins with ␣-gal epitopes following remodeling of the bone plug. Since bone plugs are trimmed to fit the femoral and tibial tunnels, release of these glycoproteins is immediate. Anti-Gal response peaked in two to eight weeks and subsequently decreased (Fig. 4B ) due to bone remodeling, fusion with the recipient's bone, and elimination of these pig bone marrow cells. Anti-Gal IgM activity posttransplantation did not change significantly (Fig. 4C) , suggesting a rapid isotype switch from IgM to IgG production. The kinetics of anti-Gal response (peak activity two to eight weeks) differs from that of anti-non gal (peak activity two to six months) (Fig. 2) . This further supports the data in Figure 1B that no ␣-gal epitopes remain within the ligament following incubation with ␣-galactosidase. If the ligament tissue presented ␣-gal epitopes, stimulation for increased anti-Gal production should have paralleled that of anti-non-gal.
Histological Demonstration of Ligamentization
The process of ligamentization can be readily demonstrated in histological sections of xenografts removed from non-evaluable subjects because of sport accidents. Processed patellar tendon (PT) tissue prior to transplantation is shown in Figure 5A . The longitudinal orientation of collagen fibers is characteristic of the tendon with fibroblast nuclei interspaced far apart of each other by collagen fibers. Ligamentization was observed at different stages in various parts of the porcine PT xenograft removed from P-06, 8.5 months posttransplantation. Initiation of ligamentization was characterized by infiltration of inflammatory cells and of fibroblasts. The fibroblasts are seen in longitudinal orientation within the region of inflammatory cells (Fig. 5B) . Ultimate proof of identifying these infiltrating fibroblasts as human cells requires the use of an assay demonstrating presence of human specific DNA sequences. This analysis could not be performed with the tissue fragments removed from the transplanted patient since they were fixed immediately and subjected to histological analysis. Vascularization of the xenograft is represented in Figure 5C as high endothelium venules and capillaries detected near inflammatory sites. Following the activity of inflammatory cells, numerous infiltrating fibroblasts align along the collagen fibers scaffold (Fig. 5D) . Ligamentization does not occur simultaneously in all regions of the xenograft, as indicated in the lower part of Figure 5D , where no ligamentization is detected. After they secrete collagen fibers, fibroblasts repopulating the xenograft and the intercellular matrix displays architecture characteristic to ACL (Fig. 5E) . The de novo secretion of collagen by the infiltrating fibroblasts is further demonstrated in trichrome staining (Fig. 5F ), where blue regions represent pig collagen, whereas newly synthesized collagen is stained in red. These histological features were also observed in porcine PT specimens removed from other nonevaluable subjects (not shown).
DISCUSSION
The present study describes the successful long-term use of immunochemically modified porcine patellar tendon (PT) for reconstruction of human ruptured ACL. In order to prevent rapid rejection and allow for appropriate ligamentization, the ␣-gal epitopes were enzymatically removed from the pig ligament and collagen fibers moderately cross-linked. In five of six evaluable subjects, porcine PT xenografts are continuing to function for more than two years, while they are gradually replaced by host tissue with ACL morphology. These results suggest that transplantation of the modified porcine PT may be considered as a treatment for ruptured ACL, despite the immune response to xenograft antigens.
A major manifestation of the measured anti-xenograft immune response in recipients of processed porcine PT is the production of anti-non-gal antibodies. These antibodies readily bind in vitro to fragmented pig ligament. A similar in vivo binding to the xenograft is likely to mediate xenograft rejection by a chronic inflammatory process. These antibodies are directed against multiple pig proteins. Since pigs and humans have evolved along separate mammalian lineages for ϳ75 million years, they have accumulated multiple mutations that result in sequence differences in most homologous genes (26 -29) . Thus, many pig proteins are immunogenic in humans, eliciting production of anti-non gal antibodies of many specificities.
Since anti-Gal antibodies were effectively removed from the sera prior to analysis by adsorption on rabbit red cells (12) , the anti-non gal antibody activity is unlikely to be directed against carbohydrate epitopes. Moreover, no immunogenic carbohydrate epitopes, other than the ␣-gal epitope, have been reported on pig nucleated cells. Nevertheless, we can not exclude the possibility that a proportion of anti-nongal antibodies may be directed toward an unknown immunogenic carbohydrate epitope within the pig xenograft.
Anti-non gal antibodies are important to the ligamentization process as they are likely to contribute to the inflammation which is necessary for initiation of ligamentization. Production of these antibodies decreases after it peaks in the period of two to six months, and returns to the pretransplantation level after 24 months. Taken together with the histological observations on the ligamentization of PT xenografts, the data suggest that by two years posttransplantation, most of the pig antigens have been eliminated by the ligamentization process and the antigenic stimulation for production of anti-non-gal antibodies is diminished. It is probable that helper T cell response to pig immunogenic peptides contributes to the production of anti-non-gal antibodies against xenoproteins. It is unlikely that cytotoxic T cells play an important role in the observed inflammatory process because no live pig cells are present in the xenograft. ACL function is not impaired during the process of gradual ligamentization. This is enabled by the moderate cross-linking of collagen fibers with glutaraldehyde. Without this cross-linking, the immune mediated destruction of the pig ligament is likely to occur at a pace that is too fast to allow for ligamentization and maintenance of appropriate structural and morphological architecture of the xenograft. Conversely, if cross-linking would have been extensive, as in inert bioprosthetic pig heart valves (incubation within 0.2-0.3% glutaraldehyde for weeks), the tissue would have become impenetrable to cellular repopulation (29) , so that the no ligamentization would occur. Since cross-linked collagen fibers are thorn as a result of repeated stretching due to leg movement, lack of repair by ligamentization would ultimately result in failure of the reconstructed ACL. The glutaraldehyde concentration of 0.1% was determined empirically as the appropriate concentration for processing porcine PT. ␣-Galactosidase treated porcine PTs that were incubated in 0.01% glutaraldehyde for cross-linking, were subsequently rejected in rhesus monkeys at a pace that was too fast to allow for proper ligamentization. This rejection was the result of extensive infiltration of inflammatory cells within two months posttransplantation. In contrast, ␣-galactosidase treated porcine PTs that were incubated with 0.1% glutaraldehyde, and subsequently transplanted into rhesus monkeys, displayed appropriate ligamentization, similar to that described in Figure 5 (unpublished data).
An important part in the processing of pig ligament xenografts is the elimination of ␣-gal epitopes by ␣-galactosidase. While glutaraldehyde cross-links protein chains, it does not affect ␣-gal epitopes. Binding of anti-Gal to ␣-gal epitopes on the cross-linked tissue is likely to enhance immune rejection so that it may exceed the rate of ligamentization. Moreover, these epitopes stimulate the immune system to produce increased amounts of high affinity anti-Gal which further exacerbates the xenograft rejection (11, 25) . This increased anti-Gal response was observed not only in patients receiving live xenograft cells, but also in patients implanted with glutaraldehyde fixed pig heart valves (30) . Since elderly individuals produce anti-Gal at lower levels than young individuals (31), it is possible that the fast one to two year deterioration of pig valve function in young individual is associated with age related differences in production of natural and elicited anti-Gal antibodies. We have observed that implantation of untreated PT in rhesus monkey increases anti-Gal titer by ϳ100 fold within two weeks (in preparation). All these findings strongly suggest that if ␣-gal epitopes are not removed, subsequent binding of natural and elicited anti-Gal is likely to be detrimental to the long term function and ligamentization of the pig PT in the recipient. This anti-Gal response might have contributed also to the strong inflammatory responses in previous failures in humans of glutaraldehyde fixed xenograft ACL from bovine origin (32, 33) . Because of unknown reasons, expression of ␣-gal epitopes is much higher in porcine and bovine tissues than in similar tissues from many other mammalian species (24, 34) . No comparative studies could be performed with pig PT expressing ␣-gal epitopes since the clinical trial requires maximizing the decrease in immunogenicity of the implant in humans.
Overall, our data suggest that the processed porcine PT is appropriate for replacing ruptured human ACL. Within two years posttransplantation, most, and possibly all the pig tissue is replaced by repopulating recipient's fibroblasts that secrete the matrix in the process of ligamentization. This process is associated with anti-non-gal immune response. These observations further suggest that, unless properly controlled, anti-non-gal response is likely to persist as long as there are pig xenoantigens in xenograft recipients. Suppression of this antinon-gal antibody response requires the prevention of activity of many B cell clones producing antibodies against the multiple pig xenoantigens. Careful monitoring of these antibodies in primate recipients of live organ xenograft, by assays similar to these in the present study, will enable investigators to determine whether prevention of long-term rejection requires complete suppression of anti-non-gal antibody response, or whether such grafts can survive under low-level production of these antibodies.
